4d pharma PLC and its subsidiaries are in the business of research and development and production of live biotherapeutic products. The company develops biotherapeutic products for diseases such as cancer, asthma, autism, and autoimmune conditions such as arthritis and multiple sclerosis. Its developing science includes Live biotherapeutics, Microbiome, MicroRx, MicroDx, and others.
相关临床试验
1
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
1
100.0%
暂无批准数据
- The global microbiome oncology market is forecast to grow from USD 353.20 million in 2026 to USD 1.94 billion by 2031, representing a compound annual growth rate of 40.7%. - Scientific evidence increasingly links gut microbiota composition to immune regulation, inflammation, and patient response to immune checkpoint inhibitors targeting PD-1, PD-L1, and CTLA-4. - Melanoma and colorectal cancer dominate research focus, with next-generation sequencing leading as the primary technology and immunotherapy enhancement as the key application. - Key players include Seres Therapeutics, Vedanta Biosciences, MaaT Pharma, Enterome, and 4D Pharma, with multiple pipeline candidates in Phase I through Phase III clinical trials.
- A comprehensive new industry report analyzes over 1,670 clinical-stage partnering agreements in pharma and biotech from 2020-2025, providing unprecedented access to deal structures and financial terms. - The report reveals detailed intelligence on how licensing agreements typically grant exclusive rights across Phase I-III trials, with multi-component structures involving collaborative R&D and commercialization strategies. - Business development professionals can now access actual contract documents and payment triggers often missing from press releases, enabling more effective negotiation strategies and competitive deal structuring.
